2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Saad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.
Saad Z. Usmani, MD, MBA, FACP, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the rapidly evolving treatment landscape in multiple myeloma.
Due to the fast pace of development in multiple myeloma, it can be difficult to remain updated on all emerging data and apply that information to clinical practice, Usmani says. This makes it important to engage with colleagues to discuss these data, Usmani adds.
Hearing new data in the context of the treatment landscape is important for clinicians both in the academic and community settings, Usmani continues. By remaining updated on emerging agents and pivotal clinical trials exploring new options, clinicians can provide the best access to treatment for their patients, Usmani concludes.